About this item:

54 Views | 27 Downloads

Author Notes:

See publication for full list of authors.

Correspondence to Professor Jonathon B. Cohen, First Author: Oscar Calzada, Department of Hematology and Medical Oncology, Emory University – Winship Cancer Institute, 1365C Clifton Road, NE Room C5006, Atlanta, GA 30322, Ph: 404-778-3942, Fax: 404-778-3366, jonathon.cohen@emory.edu

JBC designed the study.

OC, JJM, KAB, NG, SM, SIP, MG, AD, NE, TSF, and MH collected data and participated in quality control.

OC, JMS and JBC conducted data analysis and interpreted the data.

OC and JBC wrote the first version of the manuscript.

JMS, JJM, KAB, NG, SM, SIP, MG, AD, NE, TSF, MH and CRF analyzed the data and substantially edited the manuscript.

All authors reviewed and approved the final manuscript.

The authors have declared no conflicts of interest.


Research Funding:

This work received grant funding from the Lymphoma Research Foundation and the American Society of Hematology.

Research reported in this publication was supported in part by the Biostatistics and Bioinformatics Shared Resource of Winship Cancer Institute of Emory University and NIH/NCI under award number P30CA138292.


  • Science & Technology
  • Life Sciences & Biomedicine
  • Oncology
  • Hematology
  • Mantle cell lymphoma
  • deferred therapy
  • non-Hodgkin's lymphoma
  • KI-67
  • TP53
  • MIPI

Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma


Journal Title:

Leukemia & Lymphoma


Volume 59, Number 12


, Pages 2862-2870

Type of Work:

Article | Post-print: After Peer Review


Prospective identification of candidates for deferred therapy is not standardized and many patients receive immediate therapy regardless of risk. We conducted a retrospective, multi-center cohort analysis of MCL patients with comprehensive clinical data to examine the use and safety of deferred therapy for newly diagnosed patients. Previously untreated patients ≥18 years-old with MCL diagnosed in 1993–2015 at five academic sites were included. Of 395 patients, 72 (18%) received deferred therapy (defined as receipt of first treatment >90 days following initial diagnosis). Patients receiving deferred therapy were more likely to have an ECOG performance status of 0 (67 versus 44% p =.001), have no B symptoms (83 versus 65% p =.003) and have normal LDH levels at diagnosis (87 versus 55% p <.001). In multivariable analysis, deferred therapy was not associated with a significant difference in OS (HR 0.64: 95% CI 0.22–1.84, p =.407).

Copyright information:

© 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.

Export to EndNote